🔎 Trials Near Me

Home › Cancro del polmone non a piccole cellule › Illinois › Chicago

Studi clinici su Cancro del polmone non a piccole cellule a Chicago, IL

61 studi su Cancro del polmone non a piccole cellule cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

In reclutamentoFase 3
  • John H Stroger Jr Hospital of Cook County, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e altri 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

In reclutamentoFase 3
  • The University of Chicago Medical Center ( Site 0118), Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

In reclutamentoFase 3
  • University of Illinois Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06472245

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

In reclutamentoFase 2
  • Rush MD Anderson Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07293247

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

In reclutamentoFase 1
  • University of Chicago Hospital, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

In reclutamentoFase 1
  • Exelixis Clinical Site #26, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT05176483

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

In reclutamentoFase 2
  • University of Illinois Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06172478

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

In reclutamentoFase 3
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

In reclutamentoFase 3
  • University of Chicago Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07361497

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

In reclutamentoFase 3
  • University of Illinois Cancer Center, Chicago
  • Center for Care and Discovery, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06881784

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

In reclutamentoFase 3
  • University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago
  • University of Illinois Hospital and Health Sciences System, Chicago
  • Illinois Cancer Specialists, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

In reclutamentoFase 1
  • Research Site, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06218914

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

In reclutamentoFase 2
  • Rush University Medical Center Rush University Cancer Center Chicago, Chicago
  • University of Illinois at Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

In reclutamentoFase 2
  • Rush University Medical Center, Chicago
  • University of Illinois Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

In reclutamentoFase 3
  • Research Site, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

In reclutamentoFase 3
  • City of Hope, Chicago, Chicago
  • University of Illinois at Chicago, Chicago
  • University of Chicago Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06890598

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

In reclutamentoFase 2
  • Research Site, Chicago
Età da 18 a 95 · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05061550

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

In reclutamentoFase 2
  • University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06568939

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

In reclutamentoFase 2/3
  • Rush University Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07100080

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

In reclutamentoFase 1
  • Northwestern University Feinberg School of Medicine, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 set 2026 · NCT05983432

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

In reclutamentoFase 3
  • Clinical Study Site, Chicago
  • Clinical Study Site, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 set 2026 · NCT06767514

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

In reclutamentoFase 3
  • Northwestern University, Chicago
  • University of Illinois Hospital and Health Sciences System, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

In reclutamentoFase 2/3
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT04613596

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

In reclutamentoFase 2
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT04302025

A Phase 1/1b Study of IAM1363 in HER2 Cancers

In reclutamentoFase 1
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06253871

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

In reclutamentoFase 3
  • University of Illinois at Chicago, Chicago
  • University of Chicago Hospital, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

In reclutamentoFase 1
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07361562

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

In reclutamentoFase 3
  • Research Site, Chicago
  • Research Site, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07291037

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

In reclutamentoFase 3
  • University of Chicago Medical Center ( Site 0145), Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT06422143

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

In reclutamentoFase 3
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT06500481

SMP-3124LP in Adults With Advanced Solid Tumors

In reclutamentoFase 1/2
  • Northwestern Medicine Cancer Center, Chicago
  • The University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT06526819

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

In reclutamentoFase 1/2
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT06706076

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

In reclutamentoFase 1/2
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 lug 2026 · NCT05098132

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

In reclutamentoFase 3
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT06686771

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

In reclutamentoFase 1
  • UChicago Medicine - River East, Chicago
  • The University Of Chicago, Chicago
  • University of Chicago Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT04389632

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

In reclutamentoFase 1
  • University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
  • University of Chicago Medical Center /ID# 276271, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT05005403

A Study of LY4175408 in Participants With Advanced Cancer

In reclutamentoFase 1
  • The University of Chicago Medical Center (UCMC), Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 giu 2026 · NCT07046923

Study of XB010 in Subjects With Solid Tumors

In reclutamentoFase 1
  • University of Chicago Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06545331

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

In reclutamentoFase 2
  • o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 giu 2026 · NCT07603856

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 giu 2026 · NCT05642572

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

In reclutamento
  • Northwestern University, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 mag 2026 · NCT05802186

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

In reclutamentoFase 1/2
  • University of Chicago, Chicago
Età 12 e oltre · Tutti i sessi · Aggiornato il 27 mag 2026 · NCT03093116

Segmentectomy After Induction Therapy (SAINT)

In reclutamento
  • Northwestern University, Chicago
Età da 18 a 89 · Tutti i sessi · Aggiornato il 26 mag 2026 · NCT06496659

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 mag 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

In reclutamentoFase 2
  • Northwestern University, Chicago
  • John H Stroger Jr Hospital of Cook County, Chicago
18 Minutes · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06031688

Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

In reclutamentoFase 2
  • University of Illinois Cancer Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04317534

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

In reclutamentoFase 2/3
  • Northwestern University, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT06616584

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

In reclutamentoFase 1/2
  • Northwestern Memorial Hospital, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 apr 2026 · NCT06810544

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

In reclutamentoStudio osservazionale
  • John H Stroger Jr Hospital of Cook County, Chicago
  • Advocate Illinois Masonic Medical Center, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT06418204

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

In reclutamento
  • Jesse Brown VA Medical Center, Chicago, IL, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 nov 2025 · NCT06671613

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

In reclutamentoStudio osservazionale
  • Massive Bio SYNERGY-AI site, Chicago
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

In reclutamentoFase 1
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2025 · NCT05107674

I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

In reclutamentoStudio osservazionale
  • University of Chicago, Chicago
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 gen 2023 · NCT05537922

Studi su Cancro del polmone non a piccole cellule in altre città

Altri studi a Chicago

Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.